Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The purported value of empirical therapy to cover methicillin-resistant Staphylococcus aureus (MRSA) has been debated for decades. The purpose of this study was to evaluate the effects of inappropriate empirical antibiotic therapy on clinical outcomes in patients with healthcare-associated MRSA bacteremia (HA-MRSAB). METHODS: A prospective, multicenter, observational study was conducted in 15 teaching hospitals in the Republic of Korea from February 2010 to July 2011. The study subjects included adult patients with HA-MRSAB. Covariate adjustment using the propensity score was performed to control for bias in treatment assignment. The predictors of in-hospital mortality were determined by multivariate logistic regression analyses. RESULTS: In total, 345 patients with HA-MRSAB were analyzed. The overall in-hospital mortality rate was 33.0 %. Appropriate empirical antibiotic therapy was given to 154 (44.6 %) patients. The vancomycin minimum inhibitory concentrations of the MRSA isolates ranged from 0.5 to 2 mg/L by E-test. There was no significant difference in mortality between propensity-matched patient pairs receiving inappropriate or appropriate empirical antibiotics (odds ratio [OR] = 1.20; 95 % confidence interval [CI] = 0.71-2.03). Among patients with severe sepsis or septic shock, there was no significant difference in mortality between the treatment groups. In multivariate analyses, severe sepsis or septic shock (OR = 5.45; 95 % CI = 2.14-13.87), Charlson's comorbidity index (per 1-point increment; OR = 1.52; 95 % CI = 1.27-1.83), and prior receipt of glycopeptides (OR = 3.24; 95 % CI = 1.08-9.67) were independent risk factors for mortality. CONCLUSION: Inappropriate empirical antibiotic therapy was not associated with clinical outcome in patients with HA-MRSAB. Prudent use of empirical glycopeptide therapy should be justified even in hospitals with high MRSA prevalence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Design of Observational Studies
Rosenbaum, P. R. (2010) · Springer Series in Statistics · doi:10.1007/978-1-4419-1213-8 · Cited by 1,150
Lodise, T. P., McKinnon, P. S., Swiderski, L., & Rybak, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375057 · Cited by 604 · cited 1×
“1 %, which is comparable to the range from 29 % to 45 % reported in other studies [10, 12, 16, 36].”
ResultYu, V. L., Chiou, C. C. C., Feldman, C., Ortqvist, A., Rello, J., Morris, A. J., Baddour, L. M., Luna, C. M., Snydman, D. R., Ip, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/377534 · Cited by 451
Paul, M., Kariv, G., Goldberg, E., Raskin, M., Shaked, H., Hazzan, R., Samra, Z., Paghis, D., Bishara, J., & Leibovici, L. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq373 · Cited by 224 · cited 3×
“[21] speculated that the studies did not confirm an advantage to empirical vancomycin treatment, as the prevalence of vancomycin MICs >1.”
BackgroundKhatib, R., Saeed, S., Sharma, M., Riederer, K., Fakih, M. G., & Johnson, L. B. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0096-0 · Cited by 156 · cited 2×
“By contrast, six other studies reported an opposite result [11, 15, 16, 19, 20, 34].”
ResultGómez, J., García-Vázquez, E., Baños, R., Canteras, M., Ruiz, J., Baños, V., Herrero, J. A., & Valdés, M. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0272-x · Cited by 81
Fang, C.-T., Shau, W.-Y., Hsueh, P.-R., Chen, Y.-C., Wang, J.-T., Hung, C.-C., Huang, L. Y. L., & Chang, S.-C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl006 · Cited by 53
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Van Heuverswyn, J., Valik, J. K., Desirée van der Werff, S., Hedberg, P., Giske, C., & Nauclér, P. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac727 · Cited by 163
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Self-citation
Metadata
- Authors
- Yoon, Y. K., Park, D. W., Sohn, J. W., Kim, H. Y., Kim, Y.-S., Lee, C.-S., Lee, M. S., Ryu, S.-Y., Jang, H.-C., Choi, Y. J., Kang, C.-I., Choi, H. J., Lee, S. S., Kim, S. W., Kim, S. I., Kim, E. S., Kim, J. Y., Yang, K. S., Peck, K. R., & Kim, M. J.
- Venue
- BMC Infectious Diseases
- Published
- 2016-07-15
- Volume
- 16
- Issue
- 1
- Pages
- 331-331
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2472830515
- Cited by
- 34
- References
- 8
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis. https://app.cochat.ai/papers/10.1186/s12879-016-1650-8
- The paper
- Yoon, Y. K., Park, D. W., Sohn, J. W., Kim, H. Y., Kim, Y.-S., Lee, C.-S., Lee, M. S., Ryu, S.-Y., Jang, H.-C., Choi, Y. J., Kang, C.-I., Choi, H. J., Lee, S. S., Kim, S. W., Kim, S. I., Kim, E. S., Kim, J. Y., Yang, K. S., Peck, K. R., & Kim, M. J. (2016). Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-016-1650-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.